Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
BMY
Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
|
$122.49B |
$60.17
+2.06%
|
|
VRTX
Vertex Pharmaceuticals Incorporated
Vertex is a large-cap pharma/biotech with a diversified, revenue-generating portfolio anchored by CFTR modulators and expanding pipeline.
|
$111.94B |
$441.08
+1.25%
|
|
CVS
CVS Health Corporation
CVS retails OTC analgesics and related pain relief products.
|
$98.13B |
$77.25
+0.61%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
|
$78.88B |
$750.82
+0.65%
|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda is a large-cap pharmaceutical company with a diversified, high-revenue drug portfolio and pipeline.
|
$55.67B |
$17.82
+0.25%
|
|
ZTS
Zoetis Inc.
Zoetis markets vaccines for companion animals and livestock, a major revenue and product category.
|
$53.93B |
$122.38
+2.81%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$51.82B |
$849.68
+2.57%
|
|
CAH
Cardinal Health, Inc.
Nuclear medicine radiopharmaceuticals distribution and related imaging agents.
|
$50.84B |
$214.00
+0.42%
|
|
IDXX
IDEXX Laboratories, Inc.
IDEXX launched the IDEXX Cancer Dx panel, a cancer diagnostic test aligned with companion diagnostics for oncology.
|
$47.05B |
$589.76
+3.48%
|
|
BDX
Becton, Dickinson and Company
BD develops drug delivery platforms and related biologic‑delivery solutions for therapeutics including GLP‑1s and wearables.
|
$45.25B |
$158.53
+2.40%
|
|
HLN
Haleon plc
Panadol and other analgesics position Haleon in OTC Pain Relief & Analgesics.
|
$44.28B |
$9.74
+1.62%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$40.91B |
$309.87
-3.20%
|
|
ALC
Alcon Inc.
Alcon markets ophthalmic drugs and prescription eye drops like Tryptyr.
|
$39.94B |
$81.33
+2.24%
|
|
ONC
BeOne Medicines Ltd.
Core oncology-focused biotech; primary business segment is oncology therapeutics.
|
$35.87B |
$323.52
+0.88%
|
|
A
Agilent Technologies, Inc.
BIOVECTRA acquisition expands Agilent's contract manufacturing capabilities (CDMO) for advanced modalities.
|
$34.55B |
$121.86
+3.05%
|
|
GEHC
GE HealthCare Technologies Inc.
GE HealthCare markets proprietary radiopharmaceuticals (e.g., Flyrcado) and radiopharmaceutical diagnostics.
|
$34.01B |
$74.64
+1.97%
|
|
JBL
Jabil Inc.
Aseptic filling and dry oral dosage capabilities via Pharmaceutics International (Pii) reflect contract manufacturing services in pharma.
|
$33.97B |
$321.61
+3.71%
|
|
KVUE
Kenvue Inc.
Kenvue directly manufactures and sells OTC analgesics (e.g., Tylenol).
|
$33.74B |
$17.61
+0.86%
|
|
INSM
Insmed Incorporated
Brensocatib is an oral small molecule therapeutic targeting DPP1, a core part of Insmed's pipeline.
|
$30.81B |
$144.51
+1.20%
|
|
IQV
IQVIA Holdings Inc.
IQVIA operates as outsourced drug development and clinical research services akin to a CRO.
|
$30.00B |
$176.43
+2.60%
|
|
RVMD
Revolution Medicines, Inc.
Clinical-stage biotech focused on oncology; primary products are RAS(ON) inhibitors for cancer.
|
$28.73B |
$148.53
-0.50%
|
|
BIIB
Biogen Inc.
Biogen's LEQEMBI is an Alzheimer's disease therapeutic, a direct product the company manufactures and sells.
|
$26.02B |
$177.33
+0.74%
|
|
UTHR
United Therapeutics Corporation
UTHR's core PAH/CV therapy portfolio centers on prostacyclin cardiovascular drugs, including Tyvaso, Remodulin, Orenitram, and Ralinepag (where applicable).
|
$25.33B |
$588.10
+1.31%
|
|
BNTX
BioNTech SE
BioNTech develops and sells vaccines, including its mRNA vaccine platform, a core direct product category.
|
$24.75B |
$102.82
+0.69%
|
|
LH
Labcorp Holdings Inc.
Labcorp functions as aContract Research Organization offering outsourced drug development and regulatory support services.
|
$22.44B |
$270.80
+1.67%
|
|
BWXT
BWX Technologies, Inc.
Radiopharmaceuticals for nuclear medicine imaging and diagnostics.
|
$21.56B |
$235.64
+2.10%
|
|
MRNA
Moderna, Inc.
Direct vaccines products (Spikevax and pipeline vaccines) are Moderna's core revenue drivers and product line.
|
$20.99B |
$53.73
-1.73%
|
|
ROIV
Roivant Sciences Ltd.
Immunovant's FcRn-targeting therapies (e.g., IMVT-1402, batoclimab) are monoclonal antibody therapeutics.
|
$20.75B |
$29.80
+2.11%
|
Showing page 2 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
